Document is current

Article History

Received: 16 August 2019

Accepted: 15 November 2019

First Online: 21 November 2019

Compliance with ethical standards

:

: KS has received honoraria for board participation from Roche. GR has received honoraria from advisory boards from Abbvie. UH reports grants and personal fees from Roche, personal fees and non-financial support from Medac, personal fees and non-financial support from Bristol-Myers Squibb, personal fees from Novocure, personal fees from Novartis, personal fees from Daichii-Sankyo, personal fees from Riemser, personal fees from Noxxon, personal fees from AbbVie, personal fees from Bayer. MiW has received research grants from Abbvie, Adastra, Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Piqur and Roche, and honoraria for lectures or advisory board participation or consulting from Abbvie, Basilea, Bristol Meyer Squibb (BMS), Celgene, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Roche and Tocagen. The other authors report no conflicts of interest.

: The datasets of the study are available from the corresponding author on reasonable request and provided that the request is in line with the regulations of the review committees.

: This study was approved by the responsible review committees of the participating centers of the German Glioma Network in Germany () (353/2003 V) and the University Hospital Zurich, Switzerland (2015-0437). The study was performed in accordance with the Declaration of Helsinki.